{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:51:51Z","timestamp":1774659111010,"version":"3.50.1"},"reference-count":125,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJM"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5662\/wjm.v3.i4.45","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T04:58:51Z","timestamp":1408942731000},"page":"45","source":"Crossref","is-referenced-by-count":10,"title":["An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications"],"prefix":"10.5662","volume":"3","author":[{"given":"Marlein Miranda","family":"Cona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11102120"},{"key":"ref2","unstructured":"Li J. OncoCidia. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http: \/\/www.aeschylus-philanthropy.eu\/index.php\/b\/project\/oncocidia\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http: \/\/www.aeschylus-philanthropy.eu\/index.php\/b\/project\/oncocidia<\/ext-link>."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2007.03.007"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2008.12.018"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-005-9045-8"},{"key":"ref6","unstructured":"Ni Y, Bormans G, Marchal G, Verbruggen A. Tissue infarction and necrosis specific compounds (of hypericin derivatives). Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.google.com\/patents\/EP1651201B1\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.google.com\/patents\/EP1651201B1<\/ext-link>."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-0013-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2009.01.017"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1021\/ct100528u"},{"key":"ref10","unstructured":"Cancer Research UK. Cancer Worldwide - the global picture. Future trends. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http: \/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/world\/cancer-worldwide-the-global-picture\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http: \/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/world\/cancer-worldwide-the-global-picture<\/ext-link>."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0883-1"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0652-6"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25987"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"McEwan AJ, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 1994;15:499-504.","DOI":"10.1097\/00006231-199407000-00002"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181728a45"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.044"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Micallef IN. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin&rsquo;s lymphoma. Clin Lymphoma 2004;5 Suppl 1:S27-S32.","DOI":"10.3816\/CLM.2004.s.006"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023393756"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0078"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1090-0"},{"key":"ref21","unstructured":"Sharkey RM. Radioimmunotherapy against the tumor vasculature: A new target? J Nucl Med 2006;47:1070-1074."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(00)00241-8"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607761103"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2013"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.05.027"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, Yun A, Taylor CR, Epstein AL. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 1998;13:255-268.","DOI":"10.1089\/cbr.1998.13.255"},{"key":"ref27","unstructured":"Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842-5848."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(71)90073-9"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1993.12.689"},{"key":"ref31","unstructured":"Chen FM, Taylor CR, Epstein AL. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578-4585."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, Santacroce R, Di Corcia MG, Lucchese A, Dini L. Cell death: apoptosis versus necrosis (review). Int J Oncol 2002;21:165-170.","DOI":"10.3892\/ijo.21.1.165"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.150"},{"key":"ref34","unstructured":"Walker NI, Harmon BV, Gob&eacute; GC, Kerr JF. Patterns of cell death. Methods Achiev Exp Pathol 1988;13:18-54."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.10.044"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.08.004"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio711"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1096645"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.037"},{"key":"ref40","unstructured":"Nanji AA, Hiller-Sturmh&ouml;fel S. Apoptosis and necrosis: two types of cell death in alcoholic liver disease. Alcohol Health Res World 1997;21:325-330."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1152\/nips.01519.2004"},{"key":"ref42","unstructured":"Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http: \/\/www.humpath.com\/spip.php?article4548\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http: \/\/www.humpath.com\/spip.php?article4548<\/ext-link>."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.243"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.579097"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.108"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1089\/108497803322702897"},{"key":"ref47","unstructured":"Anderson PM, Wiseman GA, Lewis BD, Charboneau W, Dunn WL, Carpenter SP, Chew T. A phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131I-chTNT-1\/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Ther 2003;1:283-291."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1628"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03924-X"},{"key":"ref50","unstructured":"Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80 Suppl 1:57-64."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marm&eacute; D, Lorusso PM. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-420.","DOI":"10.1158\/1078-0432.416.11.2"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms11020562"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Wolfender JL, Queiroz EF, Hostettmann K. Photochemistry In: Birkh&auml;user Verlag. St. John's Wort and its Active Principles in Depression and Anxiety. Basel; 2005;5-19.","DOI":"10.1007\/3-7643-7338-5_2"},{"key":"ref54","unstructured":"Dewick PM. Aromatic Polyketides. Structural Modifications: Anthraquinones. Medicinal natural products: a biosynthetic approach, 2nd ed. West Sussex; 2002;63-71."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s706-002-8246-x"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/BF00817311"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000105"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/PL00010243"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1021\/jp109661c"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.2010.00847.x"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.59.5.0011"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA 1988;85:5230-5234.","DOI":"10.1073\/pnas.85.14.5230"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.1430"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2001)0740120AC"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7052.253"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol 2005;40:526-535.","DOI":"10.1097\/01.rli.0000171811.48991.5a"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2001)0740172IO"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.086116"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.4103\/1450-1147.89780"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.812"},{"key":"ref71","unstructured":"Sun ZP, inventor . Iodogen method for preparation of radioiodinated Hypericin. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.google.com\/patents\/CN101475461B?cl=zh\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.google.com\/patents\/CN101475461B?cl=zh<\/ext-link>."},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2003.10.007"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.7150\/thno.4924"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1159-4"},{"key":"ref76","unstructured":"Laurent A, Mottu F, Chapot R, Zhang JQ, Jordan O, R&uuml;fenacht DA, Doelker E, Merland JJ. Cardiovascular effects of selected water-miscible solvents for pharmaceutical injections and embolization materials: a comparative hemodynamic study using a sheep model. PDA J Pharm Sci Technol 2007;61:64-74."},{"key":"ref77","unstructured":"Reed KW, Yalkowsky SH. Lysis of human red blood cells in the presence of various cosolvents. III. The relationship between hemolytic potential and structure. J Parenter Sci Technol 1987;41:37-39."},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1021\/j150667a052"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2013.873838"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2217"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-012-0552-4"},{"key":"ref82","unstructured":"Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC. Biodistribution and therapeutic efficacy of (125\/131)I-, (186)Re-, (88\/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45:1224-1232."},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-1266.","DOI":"10.1182\/blood.V96.4.1259"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2012.05.007"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2363"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/124603"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2008-5"},{"key":"ref88","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-1475."},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.7150\/thno.5790"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Cona MM, Li J, Feng Y, Chen F, Verbruggen A, de Witte P, Oyen R, Ni Y. Targetability and Biodistribution of Radioiodinated Hypericin: Comparison between microdosing and carrier-added preparations. Anticancer Agents Med Chem 2013;Aug 28; Epub ahead of print.","DOI":"10.2174\/18715206113136660360"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2011.n.002"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00151-X"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-9574LSF"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr332"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Burke JM, Miller JE. Evaluation of multiple low doses of copper oxide wire particles compared with levamisole for control of Haemonchus contortus in lambs. Vet Parasitol 2006;139:145-149.","DOI":"10.1016\/j.vetpar.2006.02.030"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0432"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq708"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm202"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.185"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000188"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00015"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2011.12.021"},{"key":"ref103","unstructured":"Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? J Nucl Med 1993;34:1638-1641."},{"key":"ref104","unstructured":"Cosgriff PS. Thyroid blocking associated with I123- and I131 MIBG scans. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http: \/\/www.nuclearmedicine.org.uk\/thyroid\/thyweb.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http: \/\/www.nuclearmedicine.org.uk\/thyroid\/thyweb.pdf<\/ext-link>."},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2012.111"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051310"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Cona MM, Feng Y, Verbruggen A, Oyen R, Ni Y. Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats. Exp Biol Med (Maywood) 2013;Oct 21; Epub ahead of print.","DOI":"10.1177\/1535370213508235"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2012.756559"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.40.3.226"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90385-E"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90463-Y"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Frist W, Yasuda T, Segall G, Khaw BA, Strauss HW, Gold H, Stinson E, Oyer P, Baldwin J, Billingham M. Noninvasive detection of human cardiac transplant rejection with indium-111 antimyosin (Fab) imaging. Circulation 1987;76:V81-V85.","DOI":"10.1161\/01.CIR.76.2.306"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108825"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-3581(97)90105-7"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.86.6.1965"},{"key":"ref116","unstructured":"Bianco JA, Kemper AJ, Taylor A, Lazewatsky J, Tow DE, Khuri SF. Technetium-99m(Sn2+)pyrophosphate in ischemic and infarcted dog myocardium in early stages of acute coronary occlusion: histochemical and tissue-counting comparisons. J Nucl Med 1983;24:485-491."},{"key":"ref117","unstructured":"Khaw BA, Strauss HW, Moore R, Fallon JT, Yasuda T, Gold HK, Haber E. Myocardial damage delineated by indium-111 antimyosin Fab and technetium-99m pyrophosphate. J Nucl Med 1987;28:76-82."},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm588"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31829b2c6b"},{"key":"ref120","unstructured":"Vorvick LJ, Longstreth GF, Zieve D. Acute cholecystitis. MedlinePlus 2011; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http: \/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/000264.htm\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http: \/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/000264.htm<\/ext-link>."},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1996.01430160047008"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.3201\/eid1402.060763"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1086\/501557"},{"key":"ref124","unstructured":"Cantin V, Labadie R, Rhainds M, Simard FC. Intravenous contrast medium administration in computerized axial tomography at the CHUQ Medical Imaging Department. Centre hospitalier universitaire de Qu&eacute;bec Medicinal natural products: a biosynthetic approach, 2nd ed. West Sussex; 2007; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chuq.qc.ca\/NR\/rdonlyres\/03BC97EF-5F04-4375-BC48-3852965A4EDD\/0\/R%C3%89SUM%C3%89substancedecontrasteVArevised_VF.pdf.Accessed%20Nov%2029,%202010\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.chuq.qc.ca\/NR\/rdonlyres\/03BC97EF-5F04-4375-BC48-3852965A4EDD\/0\/R%C3%89SUM%C3%89substancedecontrasteVArevised_VF.pdf.Accessed%20Nov%2029,%202010<\/ext-link>."},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0b013e31823c0f87"}],"container-title":["World Journal of Methodology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T06:20:41Z","timestamp":1689488441000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/2222-0682\/full\/v3\/i4\/45.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5662\/wjm.v3.i4.45","relation":{},"ISSN":["2222-0682"],"issn-type":[{"value":"2222-0682","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}